Health plans' strategies for managing outpatient specialty pharmaceuticals
- PMID: 16966730
- DOI: 10.1377/hlthaff.25.5.1332
Health plans' strategies for managing outpatient specialty pharmaceuticals
Abstract
Balancing increased spending for specialty pharmaceuticals while providing affordable and equitable coverage for consumers is a key issue for public and private payers. Health plans rely on an array of strategies, including both medical management and those used for more traditional pharmaceuticals. To explore specific management strategies for outpatient specialty pharmaceuticals, a survey was administered to thirty-eight Blue Cross and Blue Shield plans, focused on identifying core strategies. Prior authorization was the most commonly used strategy, implemented by 83.3 percent of respondents. Other frequently implemented management strategies included claims review (82.8 percent), formulary management (76.7 percent), and utilization review (70 percent).
Similar articles
-
Managing biotechnology in a network-model health plan: a U.S. private payer perspective.Health Aff (Millwood). 2006 Sep-Oct;25(5):1347-52. doi: 10.1377/hlthaff.25.5.1347. Health Aff (Millwood). 2006. PMID: 16966732
-
Variability and growth in spending for outpatient specialty pharmaceuticals.Health Aff (Millwood). 2005 Jul-Aug;24(4):1117-27. doi: 10.1377/hlthaff.24.4.1117. Health Aff (Millwood). 2005. PMID: 16012152
-
Developing a management plan.Manag Care Q. 2003 Winter;11(1):7-10. Manag Care Q. 2003. PMID: 12790060
-
Formulary development at Regence BlueShield--a formula for success.Value Health. 2002 Jul-Aug;5(4):297-300. doi: 10.1046/j.1524-4733.2002.54002.x. Value Health. 2002. PMID: 12102692 Review. No abstract available.
-
The Blue Cross Blue Shield Association Technology Evaluation Center: how we evaluate radiology technologies.J Am Coll Radiol. 2005 Jan;2(1):33-8. doi: 10.1016/j.jacr.2004.07.002. J Am Coll Radiol. 2005. PMID: 17411757 Review.
Cited by
-
A review of approaches for the management of specialty pharmaceuticals in the United States.Pharmacoeconomics. 2014 Nov;32(11):1105-14. doi: 10.1007/s40273-014-0196-0. Pharmacoeconomics. 2014. PMID: 25118989 Free PMC article. Review.
-
US Growth Hormone Use in the Idiopathic Short Stature Era: Trends in Insurer Payments and Patient Financial Burden.J Endocr Soc. 2019 Aug 28;3(11):2023-2031. doi: 10.1210/js.2019-00246. eCollection 2019 Nov 1. J Endocr Soc. 2019. PMID: 31637343 Free PMC article.
-
Medicare formulary coverage for top-selling biologics.Nat Biotechnol. 2009 Dec;27(12):1082-4. doi: 10.1038/nbt1209-1082. Nat Biotechnol. 2009. PMID: 20010576 Free PMC article. No abstract available.
-
The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review.J Manag Care Spec Pharm. 2023 May;29(5):449-463. doi: 10.18553/jmcp.2023.29.5.449. J Manag Care Spec Pharm. 2023. PMID: 37121255 Free PMC article.
-
Demonstrating the value of biologics: a call to action.Biotechnol Healthc. 2007 Aug;4(4):33-42. Biotechnol Healthc. 2007. PMID: 23319932 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources